Compare Citius Pharmaceuticals Inc (CTXR) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Atlassian Corporation PLC — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Atlassian Corporation PLC trades at $92.44 (market cap $22.62B). The key difference: Atlassian Corporation PLC is far larger — about 1545.1× Citius Pharmaceuticals Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TEAM | |
|---|---|---|
Market Cap | $14.64M | $22.62B |
Sector | Health | Technology |
52-Week High | $1.82 | $203.00 |
52-Week Low | $0.53 | $57.15 |
Enterprise Value | $10.86M | $22.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Atlassian (TEAM) trades at $96.11, up 8.16% today, with strong technical momentum and bullish analyst sentiment. The stock shows accelerating revenue growth (32% YoY in Q3 FY26 per Zacks Investment Research, 2026-06-24) and improving margins, though it remains unprofitable. Recent earnings beats and cloud business expansion support positive outlook, while high valuation multiples and competitive pressures present risks.
Outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent net losses and elevated valuation. Wall Street consensus price target of $115.69 suggests 20% upside, though execution on profitability is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
